Core Viewpoint - The article highlights the successful implementation of a brain pacemaker for a Parkinson's disease patient, demonstrating significant improvements in mobility and quality of life through advanced neurostimulation technology [1][5][9]. Group 1: Patient Case Study - A 70-year-old patient, referred to as Long Laobo, experienced severe mobility issues due to Parkinson's disease for over a decade, including symptoms like freezing gait and hand tremors [3][7]. - After a comprehensive evaluation by a multidisciplinary team at Suzhou University-Suzhou Jiulong Hospital, the patient was deemed suitable for brain pacemaker surgery [3][5]. - Following the surgery on December 30, the patient showed initial improvements, and by January 29, the device was activated, leading to significant enhancements in gait and coordination [5][9]. Group 2: Technology and Treatment - The brain pacemaker used is a next-generation device capable of real-time monitoring and adjustment of stimulation parameters based on brain signals, offering a more precise approach to treatment compared to traditional methods [5][9]. - Deep brain stimulation (DBS) is recognized internationally as a surgical treatment for Parkinson's disease, involving the implantation of electrodes in specific brain regions to modulate abnormal neural circuits [7][9]. - The article emphasizes that patients who still respond to medication may benefit more from brain pacemaker therapy, highlighting the importance of thorough assessment and multidisciplinary collaboration in determining surgical suitability [9]. Group 3: Industry Context - Parkinson's disease affects approximately 5 million patients in China, presenting a significant public health challenge due to its complex symptoms, including both motor and non-motor issues [7]. - The advancements in neurostimulation technology are paving the way for improved treatment options for patients with Parkinson's disease and other neurological conditions, indicating a growing field of research and clinical application [9].

南财智讯1月30日电，明德生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 1200万元—1800万元，同比预减75.85%—83.90%；预计2025年全年归属于上市公司股东的扣除非经常 性损益的净利润为-9800万元—-7800万元。公司归属于上市公司股东的净利润同比下滑，主要受投资收 益、其他收益大幅下降，以及信用减值损失增加的影响。报告期内，公司获得的政府补助金额较上年同 期减少逾4000万元；受国内金融市场利率持续下行、公司理财产品收益率同比走低等因素影响，投资收 益较上年同期减少逾3000万元；公司逾期应收账款回款金额低于上年，单独进行减值测试的应收款项减 值准备转回金额较上年减少逾3000万元，从而导致信用减值损失增加。 ...

Group 1 - The company, Rendu Biotech, forecasts a net profit attributable to shareholders of 7.2 million to 10.8 million yuan for the fiscal year 2025, representing an increase of 15.01 million to 18.61 million yuan compared to the previous year, indicating a turnaround from losses to profits [1] - The primary reason for the performance change is the implementation of the "quality improvement and efficiency enhancement" action plan, which includes cost reduction and expense control measures, leading to a year-on-year decrease in period expenses [1] - During the reporting period, the company improved accounts receivable management, recovering some receivables from previous years and reversing part of the impairment losses [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers operating at full capacity, with orders scheduled until 2028, and employees working in three shifts, maintaining 24-hour production lines [1]

Core Viewpoint - Tianchen Medical (688013.SH) expects a significant increase in net profit for the year 2025, projecting a rise of 31 million to 37 million yuan, which translates to a year-on-year increase of 59.74% to 71.30% [1] Financial Performance - The company anticipates that the net profit attributable to the parent company, excluding non-recurring gains and losses, will increase by 27 million to 31 million yuan, reflecting a year-on-year growth of 57.77% to 66.32% [1] Strategic Initiatives - The company continues to adhere to an innovation-driven strategy, enhancing both domestic and international operations, and consistently providing a rich product matrix to customers [1] Product Sales - Sales revenue from the company's endoscopic stapler products has shown stable growth during the reporting period [1] Currency Impact - The company experienced an increase in foreign exchange gains due to currency fluctuations affecting its foreign currency monetary items [1]

智通财经APP讯，赛诺医疗(688108.SH)发布公告，公司预计2025年度实现归属于上市公司股东的净利 润为4300万元至5000万元，较上年同期增加4,150万元至4,850万元，同比增长2767%至3233%。 ...

Core Viewpoint - Anbipin (688393.SH) expects to report a net profit attributable to shareholders of the parent company for the year 2025 in the range of -52 million to -42 million yuan, indicating a significant loss compared to the previous year [1] Financial Performance - The anticipated loss represents a decrease of 73.29 million to 63.29 million yuan compared to the same period last year [1] - This reflects a year-on-year decline of 344.23% to 297.26% [1]

中国经济网北京1月30日讯 春立医疗(688236.SH)今日收报23.50元，跌幅6.93%。目前该股处于破 发状态。 春立医疗于2021年12月30日在上交所科创板上市，发行价格为29.81元，发行股份数量3,842.80万 股，保荐机构为华泰联合证券有限责任公司，保荐代表人为张畅、茹涛。 春立医疗上市发行募集资金总额为114,553.87万元，扣除发行费用后募集资金净额为106,712.83万 元，较原拟募集资金净额少93287.17万元。 2021年12月27日，春立医疗发布的招股书显示，公司拟募集资金200,000.00万元，用于骨科植入 物及配套材料综合建设项目、研发中心建设项目、营销网络建设项目、补充流动资金项目。 春立医疗上市发行费用合计7,841.04万元，华泰联合证券有限责任公司获得保荐费用150.00万元、 承销费用6,523.59万元。 (责任编辑：徐自立) ...

科华生物公告，预计2025年度净利润亏损5.8亿元–7.4亿元，上年同期亏损6.41亿元。报告期内，公司坚 守既定发展战略，深度研判行业发展趋势，持续迭代产品矩阵以强化核心竞争力，积极布局国内外双市 场并推进新业务提质扩容，全力护航企业可持续高质量发展。业绩影响的主要因素有：资产减值计提对 利润产生较大不利影响。行业政策叠加市场竞争加剧，量价齐跌，盈利端承压明显。 ...

Core Viewpoint - The company, Shanwaishan (688410.SH), expects to achieve a net profit attributable to shareholders of the parent company between 140 million to 159 million yuan for the year 2025, indicating a significant increase compared to the previous year [1] Financial Performance - The projected net profit represents an increase of 69.4686 million to 88.6079 million yuan compared to the same period last year [1] - This translates to a year-on-year growth of 98% to 125% [1]

益腾医疗从CT球管入手，搭建了电真空产品的研发、生产平台。公司成立于2021年，总部位于苏州昆山，拥有独立的的研发和生产和办公厂房，主要产品 包括医用CT球管、高端工业X射线管。 公司成立仅2年内便实现首款5.5MHU球管的研发落地及注册获批，为后续技术迭代与商业化推进奠定了坚实基础。 作为国内电真空技术领域的高新技术企业，益腾科技凭借创始人顶尖行业积淀、产品卓越性能及快速商业化落地能力，在高端医疗装备核心部件国产化浪潮 中脱颖而出，成功破解CT球管"卡脖子"难题。 据天眼查，益腾医疗成立于2021年，由昆山政府引进的海外高层次人才创立的高科技初创企业，聚焦于X射线管的研发与生产，产品应用于高端影像、工业 装备，填补国内空白。 创始人邹昀博士曾于清华大学、马里兰大学深造加速器和真空电子束流技术，后加入国际头部企业主导先进CT球管的研发与产品线搭建，深刻洞察CT球管 的核心技术难点与产业化痛点。 来源：猎云网 近日，昆山益腾医疗科技有限公司（简称：益腾科技）宣布完成近亿元A轮融资。本轮融资由弘晖基金领投，昆山国创集团、昆玉人才基金跟投，所募资金 将重点用于高端CT球管的研发迭代与注册推进，为公司持续领跑国产CT ...